vorinostat has been researched along with Atypical Lipomatous Tumor in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakazawa, MS | 1 |
| Eisinger-Mathason, TS | 1 |
| Sadri, N | 1 |
| Ochocki, JD | 1 |
| Gade, TP | 1 |
| Amin, RK | 1 |
| Simon, MC | 1 |
1 other study available for vorinostat and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Calcium Signaling; Cell Line, Tumor; Cell Pro | 2016 |